Terlipressin Infusion During Whipple Procedure: Effect on Blood Loss and Transfusion Needs
Terlipressin, Blood Loss

About this trial
This is an interventional treatment trial for Terlipressin
Eligibility Criteria
Inclusion Criteria:
- All patients older than 18 years of age,
- ASA classification class I and II,
- Patients assigned for Whipple procedure.
Exclusion Criteria:
- Preoperative renal failure,
- Severe liver dysfunction (Child-Turcotte-Pugh grade C),
- Hyponatremia (Na+ <132mmol/l),
- Severe valvular heart disease,
- Heart failure,
- Symptomatic coronary heart disease,
- Bradycardic arrhythmia (heart rate < 60/min),
- Peripheral artery occlusive disease (clinical stadium II-IV),
- Uncontrolled arterial hypertension (Blood pressure >160/100mmHg despite intensive treatment),
- Pregnancy.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Terlipresssin
Control
Terlipressin was started at the beginning of surgery, just after exposure of the portal vein and getting a basal portal pressure reading, as an initial bolus dose of 1 mg over 30 minutes (1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
patients received the same volume of normal saline for the same duration (50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours)